Abstract:From the early months of pregnancy and even more so later, women suffer a deficiency of iron along with a decline in their red blood cell count. It is also now clear that women who take iron supplements during pregnancy do not suffer the same post-natal reduction in hemoglobin and ferritin as those who don't make it. A study was therefore conducted on 40 women aged 20-35, with iron-deficiency anaemia during or immediately after pregnancy all of whom presented Hb < 10 gr/dl, Ht < 33% and serum iron < 60 micrograms/dl. All women with pregnancy-related pathological conditions, pre-existing on concomitant disease (Type I diabetes, heart diseases etc.) were excluded from the study. The women whose blood chemical parameters were largely homogeneous at the start of the study were divided into four treatment groups of 10 patients each and were treated as follows: Group A with oral liquid ferrous gluconate (75 mg per diem in 2 vials a day); Group B with solid ferrous gluconate (80 mg per diem in a single effervescent tablet); Group C with solid ferrous sulphate (105 mg per diem in a single tablet); and Group D with ferric protein succinylate (80 mg per diem in 2 vials a day). All were given iron treatment for 30 days. Treatment efficacy was analysed by comparing basal and final parameters using the T-test for paired dependent samples. The tolerance of the 4 treatment protocols was assessed by the analysis of any side effects such as nausea, vomiting, epigastric pain, diarrhoea, constipation or other disorders reported by patients during treatment. Results: Analysis of the therapeutic efficacy parameters (red blood cells, hemoglobin, hematocrit and serum iron) showed significant improvements but no statistically significant differences between the groups. However, the Group A patients treated with oral doses of liquid ferrous gluconate received a significantly lower cumulative dose of iron elements than the other groups: in detail 150 mg (p < 0.05) less than Groups B and D; 900 mg (< 0.001) less than Group C. By the end of treatment the Group A patients revealed significant increases versus basal values in red blood cells (p < 0.001) 1,051,000 per mm3 or 33%, in Hb (p < 0.001) 2.83 gr/dl or 32%, in Ht (p < 0.001) 8.32% or 32%, in serum iron (p < 0.05) 19.5 micrograms/dl or 61%. The same group also showed an increase in Ferritin amounting to 7.8 micrograms/dl or 24% of the basal value. As to safety, only Group A patients reported no side effects and produced no drop-outs. Gastrointestinal and other aspecific side effects caused 1 drop-out each in Groups B and C and 2 drop-outs in Group D. Conclusion: Numerous preparations containing bivalent or trivalent iron are available for the treatment of iron-deficiency anaemia during or immediately after pregnancy. It has been shown that preparations containing ferrous salts (+2) are more easily absorbed than those containing ferric salts (+3) since the former can be immediately absorbed by the duodenal mucosa. The study reported here reveals that oral ferrous gluconate in liquid form is more effective and above all better tolerated than other solid or liquid formulations containing elementary iron.

Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate

Analysis of the Effect of Iron Dextran Oral Liquid on Pediatric Nutritional Iron Deficiency Anemia

[Effectiveness and tolerability of oral liquid ferrous gluconate in iron-deficiency anemia in pregnancy and in the immediate post-partum period: comparison with other liquid or solid formulations containing bivalent or trivalent iron]

Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial

The Effectiveness and Side Effects of Ferrous Lactate Tablets for Patients with Iron Deficiency Anemia

Effect of supplementation with ferrous sulfate or iron bis-glycinate chelate on ferritin concentration in Mexican schoolchildren: a randomized controlled trial

Iron fortification of infant cereals: a proposal for the use of ferrous fumarate or ferrous succinate

COMPARISON OF ORAL IRON SUPPLEMENTS (FERROUS SULPHATE) V/S PARENTRAL IRON SUPPLEMENT (IRON SUCROSE) IN ANTENATAL PATIENTS AT DHIRAJ GENERAL HOSPITAL, VADODARA

The effect of iron absorption in ferrous gluconate form from enriched rice flour using in-vitro digestion and Caco-2 cell model

The Effect Of Iron Fortification On Iron (Fe) Status And Inflammation: A Randomized Controlled Trial

Comparison of two dosage regimens of iron in preterm infants for the prevention of iron deficiency: A prospective interventional study

Iron bioavailability from commercially available iron supplements

Amino Acid Chelated Iron versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia with Pregnancy : Randomized Controlled Trial

COMPARATIVE BIOTECHNOLOGICAL EVALUATION OF IRON SUPPLEMENTATION MODALITIES FOR PREGNANCY-RELATED ANEMIA: INTRAVENOUS IRON SUCROSE VS. ORAL FERROUS FUMARATE AND SULFATE

Safety Evaluation of Ferrous Bisglycinate Chelate

Randomized clinical trial of IV iron sucrose and IV ferric carboxymaltose in the treatment of moderate iron deficiency anaemia in pregnancy

A Systematic Review of Isotopically Measured Iron Absorption in Infants and Children Under 2 Years

A clinical study evaluating low dose ferrous fumarate vs. standard iron supplements in iron-deficient non-anemic to mild anemic adults

Low-Dose Ferrous Bisglycinate Chelate Supplementation in Chronic Kidney Disease and Hemodialysis Patients

Determination of Iron Absorption Using Erythrocyte Iron Incorporation of Two Stable Isotopes of Iron ( 57 Fe and 58 Fe) in Very Low Birthweight Premature Infants

Effect of Daily Iron Supplementation on Infantile Iron Homeostasis in Preterm Infants